Endocrine and Metabolic Science最新文献_第8页

Exploring the role of adipose tissue-derived hormones asprosin and leptin in the onset of depressive symptoms in newly diagnosed prediabetic individuals 探讨脂肪组织源性激素阿泌素和瘦素在新诊断的糖尿病前期个体抑郁症状发作中的作用

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-03-19 DOI: 10.1016/j.endmts.2025.100231

Faize Elif Bahadir , Ozlem Unay Demirel , Melike Yavuz , Ozum Firat , Irem Yogurtcu , Yavuz Govdeli , Yavuz Furuncuoglu

Background

Type 2 diabetes and depression are common chronic conditions that often co-occur, likely driven by complex mechanisms that are not yet fully understood. Chronic low-grade inflammation may serve as a shared underlying factor in both conditions. This study aimed to determine whether adipose tissue-derived hormones asprosin and leptin, particularly asprosin, which is associated with inflammatory cytokines in glucose metabolism dysregulation and has not been studied in this context—might influence the onset of depressive symptoms.

Methods

112 participants were recruited from drug-naïve individuals. Blood samples were collected, anthropometric data recorded, the Beck Depression/Anxiety Inventories administered. Adapted questions assessed physical and social activity, as well as sleep habits, to account for environmental factors. After applying the exclusion criteria, participants were divided into prediabetic (n = 32) and normoglycemic groups (n = 30).

Results

In the prediabetic group CRP was elevated (p < 0.001), with a positive correlation between asprosin and leptin (p < 0.001). Asprosin was positively correlated with TNF-α (p = 0.004), IL-6 (p = 0.002), and ESR (p < 0.001), and leptin with TNF-α (p = 0.008) and ESR (p = 0.018) but not with depressive symptoms or anxiety. Depressive symptoms were higher in prediabetic individuals with poor sleep quality.

Conclusion

In groups with similar social and physical activity levels, poor sleep quality was associated with increased depressive symptoms. While asprosin and leptin correlated with higher inflammatory cytokines, they showed no significant association with depression, possibly due to the small sample size and early-stage evaluation. Larger studies are needed to confirm any potential link between these hormones and depression.

背景2型糖尿病和抑郁症是常见的慢性疾病，经常同时发生，可能由尚未完全了解的复杂机制驱动。慢性低度炎症可能是这两种情况的共同潜在因素。本研究旨在确定脂肪组织来源的激素阿泌素和瘦素，特别是与糖代谢失调中的炎症细胞因子相关的阿泌素，是否可能影响抑郁症状的发生，但尚未在此背景下进行研究。方法从drug-naïve中招募112名受试者。采集血液样本，记录人体测量数据，进行贝克抑郁/焦虑量表。适应性问题评估了身体和社会活动，以及睡眠习惯，以解释环境因素。应用排除标准后，将参与者分为糖尿病前期组（n = 32）和血糖正常组（n = 30）。结果糖尿病前期组CRP升高(p <；0.001)，肝球蛋白与瘦素呈正相关(p <；0.001)。Asprosin与TNF-α (p = 0.004)、IL-6 （p = 0.002）、ESR (p <；0.001)，瘦素与TNF-α (p = 0.008)和ESR （p = 0.018）有关，但与抑郁症状或焦虑无关。睡眠质量差的糖尿病前期患者抑郁症状更高。结论在社交和体力活动水平相似的人群中，睡眠质量差与抑郁症状增加有关。虽然asprosin和leptin与较高的炎症细胞因子相关，但它们与抑郁症没有显着关联，可能是由于样本量小和早期评估。需要更大规模的研究来证实这些激素和抑郁症之间的潜在联系。

{"title":"Exploring the role of adipose tissue-derived hormones asprosin and leptin in the onset of depressive symptoms in newly diagnosed prediabetic individuals","authors":"Faize Elif Bahadir , Ozlem Unay Demirel , Melike Yavuz , Ozum Firat , Irem Yogurtcu , Yavuz Govdeli , Yavuz Furuncuoglu","doi":"10.1016/j.endmts.2025.100231","DOIUrl":"10.1016/j.endmts.2025.100231","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes and depression are common chronic conditions that often co-occur, likely driven by complex mechanisms that are not yet fully understood. Chronic low-grade inflammation may serve as a shared underlying factor in both conditions. This study aimed to determine whether adipose tissue-derived hormones asprosin and leptin, particularly asprosin, which is associated with inflammatory cytokines in glucose metabolism dysregulation and has not been studied in this context—might influence the onset of depressive symptoms.</div></div><div><h3>Methods</h3><div>112 participants were recruited from drug-naïve individuals. Blood samples were collected, anthropometric data recorded, the Beck Depression/Anxiety Inventories administered. Adapted questions assessed physical and social activity, as well as sleep habits, to account for environmental factors. After applying the exclusion criteria, participants were divided into prediabetic (n = 32) and normoglycemic groups (n = 30).</div></div><div><h3>Results</h3><div>In the prediabetic group CRP was elevated (p < 0.001), with a positive correlation between asprosin and leptin (p < 0.001). Asprosin was positively correlated with TNF-α (p = 0.004), IL-6 (p = 0.002), and ESR (p < 0.001), and leptin with TNF-α (p = 0.008) and ESR (p = 0.018) but not with depressive symptoms or anxiety. Depressive symptoms were higher in prediabetic individuals with poor sleep quality.</div></div><div><h3>Conclusion</h3><div>In groups with similar social and physical activity levels, poor sleep quality was associated with increased depressive symptoms. While asprosin and leptin correlated with higher inflammatory cytokines, they showed no significant association with depression, possibly due to the small sample size and early-stage evaluation. Larger studies are needed to confirm any potential link between these hormones and depression.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus 瑞舒伐他汀控制合并或不合并糖尿病的高血压患者LDL-C和非hdl - c水平的有效性

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-03-17 DOI: 10.1016/j.endmts.2025.100230

To Anh Tan Le , An Viet Tran , Son Kim Tran , Chau Minh Tran , Dang Khoa Dang Tran , Duy Huu Duong , Toan Hoang Ngo

Background

LDL-C and non-HDL-C are contributing risk factors in the development of cardiovascular disease and stroke, exacerbating hazardous cardiovascular events. Rosuvastatin is a widely used statin globally, and a thorough assessment of its efficacy in hypertensive patients with or without diabetes mellitus is essential.

Objectives

This study aims to compare the efficacy of Rosuvastatin 20 mg in controlling LDL-C and non-HDL-C in hypertensive patients with and without diabetes.

Methods

A cross-sectional descriptive study on 126 primary hypertensive patients (72 hypertensive patients with diabetes and 54 hypertensive patients without diabetes) treated with Rosuvastatin based on cardiovascular risk stratification according to SCORE to assess the efficiency of achieving treatment targets.

Results

In hypertensive patients without diabetes (n = 54; 42.9 %), the average age was higher (63.52 ± 8.68 years) and predominantly female (70.4 %) compared to those with diabetes (n = 72; 57.1 %). After 12 weeks of Rosuvastatin 20 mg treatment, non-diabetic patients exhibited more significant improvements in lipid profiles, notably marked decreases in LDL-C and non-HDL-C levels (p < 0.001). The treatment targets for LDL-C were achieved by 27.8 % of diabetic patients and 20.4 % of non-diabetic patients, while the targets for non-HDL-C were achieved by 40.3 % of diabetic patients and 41.5 % of non-diabetic patients. History of stroke and coronary artery disease was significantly associated with increased LDL-C and non-HDL-C in both pre-and post-treatment in both groups.

Conclusion

The utilization of Rosuvastatin 20 mg has shown efficacy in ameliorating elevated LDL-C and non-HDL-C levels in primary hypertensive patients. Specifically, in the hypertensive group without diabetes, Rosuvastatin 20 mg aids in better control of LDL-C and non-HDL-C compared to the hypertensive group with diabetes.

背景：ldl - c和非hdl - c是心血管疾病和中风发生的危险因素，加剧了危险的心血管事件。瑞舒伐他汀是全球广泛使用的他汀类药物，全面评估其对合并或不合并糖尿病的高血压患者的疗效至关重要。目的比较瑞舒伐他汀20mg对合并和不合并糖尿病的高血压患者LDL-C和非hdl - c的控制效果。方法对126例原发性高血压患者（伴有糖尿病的高血压患者72例，无糖尿病的高血压患者54例）进行基于心血管危险分层（SCORE）的横断面描述性研究，评价瑞舒伐他汀治疗的疗效。结果无糖尿病的高血压患者54例；42.9%)，平均年龄（63.52±8.68岁）高于糖尿病患者(n = 72；57.1%)。瑞舒伐他汀20mg治疗12周后，非糖尿病患者的脂质谱表现出更显著的改善，LDL-C和非hdl - c水平显著降低(p <；0.001)。27.8%的糖尿病患者和20.4%的非糖尿病患者达到了LDL-C的治疗目标，40.3%的糖尿病患者和41.5%的非糖尿病患者达到了非hdl - c的治疗目标。卒中和冠状动脉疾病史与两组治疗前后LDL-C和非hdl - c升高显著相关。结论瑞舒伐他汀20mg可有效改善原发性高血压患者LDL-C和非hdl - c水平升高。具体来说，在没有糖尿病的高血压组中，瑞舒伐他汀20mg比高血压合并糖尿病组更有助于控制LDL-C和非hdl - c。

{"title":"The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus","authors":"To Anh Tan Le , An Viet Tran , Son Kim Tran , Chau Minh Tran , Dang Khoa Dang Tran , Duy Huu Duong , Toan Hoang Ngo","doi":"10.1016/j.endmts.2025.100230","DOIUrl":"10.1016/j.endmts.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>LDL-C and non-HDL-C are contributing risk factors in the development of cardiovascular disease and stroke, exacerbating hazardous cardiovascular events. Rosuvastatin is a widely used statin globally, and a thorough assessment of its efficacy in hypertensive patients with or without diabetes mellitus is essential.</div></div><div><h3>Objectives</h3><div>This study aims to compare the efficacy of Rosuvastatin 20 mg in controlling LDL-C and non-HDL-C in hypertensive patients with and without diabetes.</div></div><div><h3>Methods</h3><div>A cross-sectional descriptive study on 126 primary hypertensive patients (72 hypertensive patients with diabetes and 54 hypertensive patients without diabetes) treated with Rosuvastatin based on cardiovascular risk stratification according to SCORE to assess the efficiency of achieving treatment targets.</div></div><div><h3>Results</h3><div>In hypertensive patients without diabetes (n = 54; 42.9 %), the average age was higher (63.52 ± 8.68 years) and predominantly female (70.4 %) compared to those with diabetes (n = 72; 57.1 %). After 12 weeks of Rosuvastatin 20 mg treatment, non-diabetic patients exhibited more significant improvements in lipid profiles, notably marked decreases in LDL-C and non-HDL-C levels (p < 0.001). The treatment targets for LDL-C were achieved by 27.8 % of diabetic patients and 20.4 % of non-diabetic patients, while the targets for non-HDL-C were achieved by 40.3 % of diabetic patients and 41.5 % of non-diabetic patients. History of stroke and coronary artery disease was significantly associated with increased LDL-C and non-HDL-C in both pre-and post-treatment in both groups.</div></div><div><h3>Conclusion</h3><div>The utilization of Rosuvastatin 20 mg has shown efficacy in ameliorating elevated LDL-C and non-HDL-C levels in primary hypertensive patients. Specifically, in the hypertensive group without diabetes, Rosuvastatin 20 mg aids in better control of LDL-C and non-HDL-C compared to the hypertensive group with diabetes.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100230"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment 最新的多囊卵巢综合征（PCOS），诊断标准，和新的治疗

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-03-01 DOI: 10.1016/j.endmts.2025.100228

Arghavan Ghafari , Malihe Maftoohi , Mohammadamin Eslami Samarin , Sepideh Barani , Majid Banimohammad , Reza Samie

Polycystic Ovary Syndrome (PCOS) is a prevalent reproductive disease influencing 4–20 % of women, often resulting in delayed diagnosis and correlated metabolic issues such as obesity and insulin resistance, impacting their quality of life. Diagnosis is guided according to the Rotterdam criteria, oligo-anovulation, polycystic ovary morphology, and incorporating hyperandrogenism, with Anti-Müllerian hormone as an indicator for ovary morphology. PCOS management necessitates a multifaceted approach, including lifestyle modifications, weight loss strategies, dietary adjustments, and pharmacological interventions. Lifestyle interventions, comprising exercise regimens, dietary modifications, and behavioral strategies, exhibit the potential to enhance metabolic health among PCOS patients. While no singular diet or exercise regimen emerges as superior, the Mediterranean and ketogenic diets have demonstrated favorable effects. Pharmacological interventions, such as combined oral contraceptives, metformin, and clomiphene citrate, assume pivotal roles in regulating menstrual cycles and mitigating hyperandrogenism symptoms. Personalized approaches, tailored to individual responses, are imperative for optimizing outcomes in the management of PCOS.

多囊卵巢综合征（PCOS）是一种流行的生殖疾病，影响了4 - 20%的女性，往往导致诊断延迟和相关的代谢问题，如肥胖和胰岛素抵抗，影响她们的生活质量。诊断依据鹿特丹标准，少排卵，多囊卵巢形态，合并雄激素过多，以抗勒氏激素为卵巢形态指标。多囊卵巢综合征的治疗需要多方面的方法，包括生活方式的改变，减肥策略，饮食调整和药物干预。生活方式干预，包括运动方案、饮食调整和行为策略，显示出改善多囊卵巢综合征患者代谢健康的潜力。虽然没有单一的饮食或运动方案是优越的，但地中海和生酮饮食已经证明了有利的效果。药物干预，如联合口服避孕药、二甲双胍和枸橼酸克罗米芬，在调节月经周期和减轻高雄激素症症状方面起着关键作用。个性化的方法，针对个人的反应，是优化多囊卵巢综合征管理结果的必要条件。

{"title":"The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment","authors":"Arghavan Ghafari , Malihe Maftoohi , Mohammadamin Eslami Samarin , Sepideh Barani , Majid Banimohammad , Reza Samie","doi":"10.1016/j.endmts.2025.100228","DOIUrl":"10.1016/j.endmts.2025.100228","url":null,"abstract":"<div><div>Polycystic Ovary Syndrome (PCOS) is a prevalent reproductive disease influencing 4–20 % of women, often resulting in delayed diagnosis and correlated metabolic issues such as obesity and insulin resistance, impacting their quality of life. Diagnosis is guided according to the Rotterdam criteria, oligo-anovulation, polycystic ovary morphology, and incorporating hyperandrogenism, with Anti-Müllerian hormone as an indicator for ovary morphology. PCOS management necessitates a multifaceted approach, including lifestyle modifications, weight loss strategies, dietary adjustments, and pharmacological interventions. Lifestyle interventions, comprising exercise regimens, dietary modifications, and behavioral strategies, exhibit the potential to enhance metabolic health among PCOS patients. While no singular diet or exercise regimen emerges as superior, the Mediterranean and ketogenic diets have demonstrated favorable effects. Pharmacological interventions, such as combined oral contraceptives, metformin, and clomiphene citrate, assume pivotal roles in regulating menstrual cycles and mitigating hyperandrogenism symptoms. Personalized approaches, tailored to individual responses, are imperative for optimizing outcomes in the management of PCOS.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of metabolic syndrome in the occurrence of hearing disorders in the Democratic Republic of Congo 代谢综合征对刚果民主共和国听力障碍发生的影响

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-03-01 DOI: 10.1016/j.endmts.2025.100227

Jérôme Gedikondele Sokolo , Aliocha Natuhoyila Nkodila , Gabriel Mabwaka Lema , Richard Nzanza Matanda , Pius Zakayi Kabututu , Benjamin Longo-Mbenza

Background

The assessment of hearing function in human life is important, because good hearing is important for social participation and inclusion in employment and education. The objective of this study is to evaluate the influence of metabolic syndrome in the occurrence of hearing disorders in patients followed in hospitals in Kinshasa.

Methods

This was an analytical cross-sectional study that included 400 patients consulted in 7 hospitals in the city province of Kinshasa during the period from January 2005 to September 2020. Sociodemographic, clinical, and biological data were analyzed. Multivariate logistic regression analysis and discriminant analysis were used as a basis to document the factors associated with hearing disorders in the study population; and the statistical significance threshold was p < 5 %.

Results

The frequency of hearing loss was 40.1 % in patients with metabolic syndrome. Risk factors identified for the occurrence of hearing loss in patients with metabolic syndrome were age ≥ 60 years (aOR: 2.73 95 % CI: 1.37–5.42), waist circumference > 85 cm (Female) or > 94 cm (Male) (aOR: 2.65 95 % CI: 1.37–3.72); blood glucose ≥126 mg/dL (aOR: 2.86 95 % CI: 1.32–6.17), BMI ≥25 kg/m2 (aOR: 2.73 95 % CI: 1.89–3.32) and in patients with insulinemia >10 IU/L (aOR: 3.37 95 % CI: 1.47–7.76).

Conclusion

The frequency of hearing loss is high in the population studied. The components of the metabolic syndrome were identified as independent determinants of hearing loss.

人类生活中听力功能的评估是很重要的，因为良好的听力对社会参与和就业和教育都很重要。本研究的目的是评估代谢综合征对金沙萨医院随访患者听力障碍发生的影响。方法这是一项分析性横断面研究，包括2005年1月至2020年9月期间在金沙萨市省7家医院就诊的400名患者。分析了社会人口学、临床和生物学数据。采用多变量logistic回归分析和判别分析作为基础，记录研究人群中与听力障碍相关的因素；统计学显著性阈值为p <；5%。结果代谢综合征患者听力损失发生率为40.1%。代谢综合征患者发生听力损失的危险因素为年龄≥60岁（aOR: 2.73 95% CI: 1.37 ~ 5.42）、腰围和gt；85厘米（女）或>；94 cm（男性）（aOR: 2.65 95% CI: 1.37 ~ 3.72）；血糖≥126 mg/dL (aOR: 2.86 95% CI: 1.32-6.17), BMI≥25 kg/m2 (aOR: 2.73 95% CI: 1.89-3.32)，胰岛素血症患者≥10 IU/L （aOR: 3.37 95% CI: 1.47-7.76）。结论研究人群听力损失发生率较高。代谢综合征的组成部分被确定为听力损失的独立决定因素。

{"title":"Influence of metabolic syndrome in the occurrence of hearing disorders in the Democratic Republic of Congo","authors":"Jérôme Gedikondele Sokolo , Aliocha Natuhoyila Nkodila , Gabriel Mabwaka Lema , Richard Nzanza Matanda , Pius Zakayi Kabututu , Benjamin Longo-Mbenza","doi":"10.1016/j.endmts.2025.100227","DOIUrl":"10.1016/j.endmts.2025.100227","url":null,"abstract":"<div><h3>Background</h3><div>The assessment of hearing function in human life is important, because good hearing is important for social participation and inclusion in employment and education. The objective of this study is to evaluate the influence of metabolic syndrome in the occurrence of hearing disorders in patients followed in hospitals in Kinshasa.</div></div><div><h3>Methods</h3><div>This was an analytical cross-sectional study that included 400 patients consulted in 7 hospitals in the city province of Kinshasa during the period from January 2005 to September 2020. Sociodemographic, clinical, and biological data were analyzed. Multivariate logistic regression analysis and discriminant analysis were used as a basis to document the factors associated with hearing disorders in the study population; and the statistical significance threshold was <em>p</em> < 5 %.</div></div><div><h3>Results</h3><div>The frequency of hearing loss was 40.1 % in patients with metabolic syndrome. Risk factors identified for the occurrence of hearing loss in patients with metabolic syndrome were age ≥ 60 years (aOR: 2.73 95 % CI: 1.37–5.42), waist circumference > 85 cm (Female) or > 94 cm (Male) (aOR: 2.65 95 % CI: 1.37–3.72); blood glucose ≥126 mg/dL (aOR: 2.86 95 % CI: 1.32–6.17), BMI ≥25 kg/m2 (aOR: 2.73 95 % CI: 1.89–3.32) and in patients with insulinemia >10 IU/L (aOR: 3.37 95 % CI: 1.47–7.76).</div></div><div><h3>Conclusion</h3><div>The frequency of hearing loss is high in the population studied. The components of the metabolic syndrome were identified as independent determinants of hearing loss.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100227"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distribution of norepinephrine and acetylcholine receptors in ovarian structures across reproductive and senescent phases in rats 大鼠生殖期和衰老期卵巢结构中去甲肾上腺素和乙酰胆碱受体的分布

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-02-13 DOI: 10.1016/j.endmts.2025.100225

Juan Bravo-Benítez , María E. Rivera-Castro , Cesar F. Pastelín , Ithayetsi Sarmiento , Amayrani Hernández , Alfonso Díaz , Carolina Morán

The autonomic nerves in the mammalian ovary are responsible for transmitting the neurotransmitters norepinephrine and acetylcholine, among others. Interestingly, some ovarian innervation becomes more active toward the end of life. The objective of this study was to examine the presence of adrenergic (A1R) and muscarinic (M1R) receptors in adult and senescent female rats. Female rats were divided into three groups according to age: young adults aged 3 to 5 months (3M), middle-aged rats aged 12 months (12M), and senescent rats aged 15 months (15M). Primary antibodies targeting the α1-adrenergic receptor, μ1-muscarinic receptor, 17β-estradiol receptor (ER), and α1-progesterone receptor (PR) were used. Immunoreactivity analysis covered the ovarian stroma and cells around functional structures such as the corpus luteum, ovarian cysts, and follicles. Both receptor antibodies stained these structures, but the noradrenergic binding was three times more abundant than cholinergic binding. The number of immunoreactive cells expressing the A1R/ER combination was significantly increased in 12M rats, principally around follicles or cysts. M1R/PR staining was similarly increased in the 12M group, but the principal signal source was the stroma cells. The autonomic nervous system appears to participate in the loss of function of these structures with age in the rat ovary.

哺乳动物卵巢中的自主神经负责传递去甲肾上腺素和乙酰胆碱等神经递质。有趣的是，一些卵巢神经支配在生命末期变得更加活跃。本研究的目的是检测成年和衰老雌性大鼠肾上腺素能（A1R）和毒蕈碱（M1R）受体的存在。雌性大鼠按年龄分为3 ~ 5月龄青壮年组（3M）、12月龄中年大鼠（12M）、15月龄老年大鼠（15M）。采用靶向α1-肾上腺素能受体、μ1-毒蕈碱受体、17β-雌二醇受体（ER）和α1-孕酮受体（PR）的一抗。免疫反应性分析包括卵巢间质和功能结构周围的细胞，如黄体、卵巢囊肿和卵泡。两种受体抗体都染色了这些结构，但去甲肾上腺素能结合比胆碱能结合丰富三倍。在12M大鼠中，表达A1R/ER组合的免疫反应细胞数量显著增加，主要是在卵泡或囊肿周围。12M组M1R/PR染色同样升高，但主要信号来源为基质细胞。随着年龄的增长，自主神经系统似乎参与了这些结构在大鼠卵巢中的功能丧失。

{"title":"Distribution of norepinephrine and acetylcholine receptors in ovarian structures across reproductive and senescent phases in rats","authors":"Juan Bravo-Benítez , María E. Rivera-Castro , Cesar F. Pastelín , Ithayetsi Sarmiento , Amayrani Hernández , Alfonso Díaz , Carolina Morán","doi":"10.1016/j.endmts.2025.100225","DOIUrl":"10.1016/j.endmts.2025.100225","url":null,"abstract":"<div><div>The autonomic nerves in the mammalian ovary are responsible for transmitting the neurotransmitters norepinephrine and acetylcholine, among others. Interestingly, some ovarian innervation becomes more active toward the end of life. The objective of this study was to examine the presence of adrenergic (A1R) and muscarinic (M1R) receptors in adult and senescent female rats. Female rats were divided into three groups according to age: young adults aged 3 to 5 months (3M), middle-aged rats aged 12 months (12M), and senescent rats aged 15 months (15M). Primary antibodies targeting the α1-adrenergic receptor, μ1-muscarinic receptor, 17β-estradiol receptor (ER), and α1-progesterone receptor (PR) were used. Immunoreactivity analysis covered the ovarian stroma and cells around functional structures such as the corpus luteum, ovarian cysts, and follicles. Both receptor antibodies stained these structures, but the noradrenergic binding was three times more abundant than cholinergic binding. The number of immunoreactive cells expressing the A1R/ER combination was significantly increased in 12M rats, principally around follicles or cysts. M1R/PR staining was similarly increased in the 12M group, but the principal signal source was the stroma cells. The autonomic nervous system appears to participate in the loss of function of these structures with age in the rat ovary.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100225"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monosodium glutamate (MSG) exposure induced oxidative stress and disrupted testicular hormonal regulation, exacerbating reproductive dysfunction in male WISTAR rats 味精暴露诱导氧化应激和睾丸激素调节紊乱，加剧雄性WISTAR大鼠的生殖功能障碍

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-02-10 DOI: 10.1016/j.endmts.2025.100226

Adesua Emmanuel Ogunmokunwa, Babatunde Oluwaseun Ibitoye

Background

Monosodium glutamate (MSG) is a common food additive linked to various health concerns, including potential reproductive toxicity.

Objective

To investigate the effects of chronic, low-dose MSG on testicular hormones and oxidative stress biomarkers in adult male Wistar rats.

Methods

Thirty male Wistar rats were divided into five groups (n = 6 per group). The control group received distilled water, while the experimental groups were orally administered MSG at 30, 100, 300, and 1000 mg/kg body weight for 65 days. Hormonal levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were measured using ELISA. Testicular oxidative stress markers, including malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), were assessed.

Results

MSG caused a dose-dependent decrease in LH, FSH, and testosterone levels, with the highest dose (1000 mg/kg) exhibiting the most significant reductions. MDA levels increased proportionally with MSG dosage, indicating heightened oxidative stress. Conversely, the activities of antioxidant enzymes (SOD, CAT, GSH, GPx) were significantly diminished, reflecting impaired antioxidant defences.

Conclusion

Chronic MSG exposure disrupts hormonal regulation and induces oxidative stress in a dose-dependent manner, potentially impairing male reproductive health. These findings underscore the need for further studies on the long-term reproductive effects of MSG and possible protective interventions.

味精（MSG）是一种常见的食品添加剂，与各种健康问题有关，包括潜在的生殖毒性。目的探讨慢性低剂量味精对成年雄性Wistar大鼠睾丸激素及氧化应激生物标志物的影响。方法雄性Wistar大鼠30只，随机分为5组，每组6只。对照组饲喂蒸馏水，试验组分别按30、100、300、1000 mg/kg体重口服味精，连续65 d。采用ELISA法测定促黄体生成素（LH）、促卵泡激素（FSH）、睾酮水平。评估睾丸氧化应激标志物，包括丙二醛（MDA）、谷胱甘肽（GSH）、超氧化物歧化酶（SOD）、过氧化氢酶（CAT）和谷胱甘肽过氧化物酶（GPx）。结果smsg引起LH、FSH和睾酮水平呈剂量依赖性降低，最高剂量（1000 mg/kg）降低最显著。丙二醛水平随味精剂量成比例增加，表明氧化应激升高。相反，抗氧化酶（SOD、CAT、GSH、GPx）活性显著降低，反映出抗氧化防御能力受损。结论慢性味精暴露破坏激素调节，诱导氧化应激，并呈剂量依赖性，可能损害男性生殖健康。这些发现强调需要进一步研究味精的长期生殖影响和可能的保护性干预措施。

{"title":"Monosodium glutamate (MSG) exposure induced oxidative stress and disrupted testicular hormonal regulation, exacerbating reproductive dysfunction in male WISTAR rats","authors":"Adesua Emmanuel Ogunmokunwa, Babatunde Oluwaseun Ibitoye","doi":"10.1016/j.endmts.2025.100226","DOIUrl":"10.1016/j.endmts.2025.100226","url":null,"abstract":"<div><h3>Background</h3><div>Monosodium glutamate (MSG) is a common food additive linked to various health concerns, including potential reproductive toxicity.</div></div><div><h3>Objective</h3><div>To investigate the effects of chronic, low-dose MSG on testicular hormones and oxidative stress biomarkers in adult male Wistar rats.</div></div><div><h3>Methods</h3><div>Thirty male Wistar rats were divided into five groups (<em>n</em> = 6 per group). The control group received distilled water, while the experimental groups were orally administered MSG at 30, 100, 300, and 1000 mg/kg body weight for 65 days. Hormonal levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were measured using ELISA. Testicular oxidative stress markers, including malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), were assessed.</div></div><div><h3>Results</h3><div>MSG caused a dose-dependent decrease in LH, FSH, and testosterone levels, with the highest dose (1000 mg/kg) exhibiting the most significant reductions. MDA levels increased proportionally with MSG dosage, indicating heightened oxidative stress. Conversely, the activities of antioxidant enzymes (SOD, CAT, GSH, GPx) were significantly diminished, reflecting impaired antioxidant defences.</div></div><div><h3>Conclusion</h3><div>Chronic MSG exposure disrupts hormonal regulation and induces oxidative stress in a dose-dependent manner, potentially impairing male reproductive health. These findings underscore the need for further studies on the long-term reproductive effects of MSG and possible protective interventions.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100226"},"PeriodicalIF":0.0,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acromegaly: Is earlier diagnosis possible? Exploration of a screening algorithm to select high-risk patients 肢端肥大症：早期诊断可能吗？探索一种筛选高危患者的筛选算法

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-02-07 DOI: 10.1016/j.endmts.2025.100223

Tessa N.A. Slagboom , David de Jong , Peter H. Bisschop , Madeleine L. Drent

Purpose

Given the ongoing need to reduce the delay in diagnosis of acromegaly, the aim of the current study was to develop a screening algorithm that: finds as many patients as possible who have already been diagnosed with acromegaly (=sensitivity), while identifying a limited number of additional patients who are at risk for acromegaly as a proxy for specificity.

Methods

CTcue data mining software (version 4.7, IQVIA Inc., USA) was used to develop a screening algorithm. Data were extracted from the electronic health records of a tertiary centre. Multiple sources (literature review, real-world evidence and expert opinion) were used to identify predictors such as clinical manifestations, comorbidities and frequently consulted specialists, for inclusion in the algorithm. Based on different combinations of predictors, several exploratory search strategies were constructed in CTcue and algorithms with the highest sensitivity were further adapted.

Results

A total of 68 predictors were identified and grouped into 5 categories. After exploratory analysis and fine-tuning, an algorithm combining pathognomonic changes in clinical appearance with manifestations considered by medical experts to be most characteristic of acromegaly (hyperhidrosis, sleep apnoea, arthralgia, headache and type 2 diabetes mellitus) detected 48/90 of patients with previously diagnosed acromegaly, while identifying an additional 1844/1,7 million of possible at-risk patients.

Conclusion

We found that our best algorithm led to the detection of more than half of patients with previously diagnosed acromegaly. The same algorithm identified 0.1 % of the hospital population as potentially having acromegaly, which is approximately 10 times higher than the estimated worldwide prevalence. These results seem promising but need further improvement and validation.

鉴于持续需要减少肢端肥大症的诊断延迟，本研究的目的是开发一种筛选算法：发现尽可能多的已经诊断为肢端肥大症的患者（=敏感性），同时识别有限数量的额外有肢端肥大症风险的患者作为特异性的代理。方法采用sctcue数据挖掘软件（美国IQVIA Inc. 4.7版）开发筛选算法。数据取自一家三级医疗中心的电子健康记录。多种来源（文献综述、真实世界证据和专家意见）用于确定临床表现、合并症和经常咨询专家等预测因素，以便纳入算法。基于不同的预测因子组合，在CTcue中构建了几种探索性搜索策略，并进一步调整了灵敏度最高的算法。结果共识别出68个预测因子，并将其分为5类。经过探索性分析和微调，将临床表现的病理变化与医学专家认为最具肢端肥大症特征的表现（多汗症、睡眠呼吸暂停、关节痛、头痛和2型糖尿病）相结合的算法检测出48/90先前诊断的肢端肥大症患者，同时识别出另外1844/ 170万可能的高危患者。结论我们发现，我们的最佳算法可以检测出超过一半的先前诊断为肢端肥大症的患者。同样的算法确定0.1%的医院人口可能患有肢端肥大症，这比估计的全球患病率高出约10倍。这些结果似乎很有希望，但需要进一步改进和验证。

{"title":"Acromegaly: Is earlier diagnosis possible? Exploration of a screening algorithm to select high-risk patients","authors":"Tessa N.A. Slagboom , David de Jong , Peter H. Bisschop , Madeleine L. Drent","doi":"10.1016/j.endmts.2025.100223","DOIUrl":"10.1016/j.endmts.2025.100223","url":null,"abstract":"<div><h3>Purpose</h3><div>Given the ongoing need to reduce the delay in diagnosis of acromegaly, the aim of the current study was to develop a screening algorithm that: finds as many patients as possible who have already been diagnosed with acromegaly (=sensitivity), while identifying a limited number of additional patients who are at risk for acromegaly as a proxy for specificity.</div></div><div><h3>Methods</h3><div>CTcue data mining software (version 4.7, IQVIA Inc., USA) was used to develop a screening algorithm. Data were extracted from the electronic health records of a tertiary centre. Multiple sources (literature review, real-world evidence and expert opinion) were used to identify predictors such as clinical manifestations, comorbidities and frequently consulted specialists, for inclusion in the algorithm. Based on different combinations of predictors, several exploratory search strategies were constructed in CTcue and algorithms with the highest sensitivity were further adapted.</div></div><div><h3>Results</h3><div>A total of 68 predictors were identified and grouped into 5 categories. After exploratory analysis and fine-tuning, an algorithm combining pathognomonic changes in clinical appearance with manifestations considered by medical experts to be most characteristic of acromegaly (hyperhidrosis, sleep apnoea, arthralgia, headache and type 2 diabetes mellitus) detected 48/90 of patients with previously diagnosed acromegaly, while identifying an additional 1844/1,7 million of possible at-risk patients.</div></div><div><h3>Conclusion</h3><div>We found that our best algorithm led to the detection of more than half of patients with previously diagnosed acromegaly. The same algorithm identified 0.1 % of the hospital population as potentially having acromegaly, which is approximately 10 times higher than the estimated worldwide prevalence. These results seem promising but need further improvement and validation.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100223"},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective clinical analysis of time to recovery from diabetic ketoacidosis in Ethiopia 埃塞俄比亚糖尿病酮症酸中毒患者康复时间的回顾性临床分析

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-02-06 DOI: 10.1016/j.endmts.2025.100224

Angefa Ayele , Dube Jara , Alo Edin , Digafe Hailu , Mihiret Kifle , Yohannes Fekadu

Background

Diabetes is a metabolic disorder that affected > or = 500 million people in 2021. Diabetic ketoacidosis is the most serious acute complication. Because of the significant health burden of diabetic ketoacidosis, we performed a retrospective study on the recovery time and predictors among adult diabetic mellitus patients in selected public hospitals in Southern Oromia in Ethiopia.

Methods

A retrospective follow-up study was conducted of 316 randomly selected adult diabetic ketoacidosis patients admitted between January 1, 2020, and July 31, 2023. A structured checklist was utilized. Data were entered into Epi-data version 4.6 and analyzed with STATA version 17, employing Kaplan-Meier survival curves, log-rank tests, and Cox-proportional hazards models to identify predictors. Results from bivariable and multivariable Cox-regression were reported via adjusted hazard ratio with 95 % confidence intervals.

Results

This study included 316 participants, with 256 adults (81.01 %) recovering throughout the follow-up period. The overall DKA recovery rate was 23.8 per 1000 person-hours (95 % CI: 22.21–27.07), and the median recovery time was 42 hr. Significant predictors of recovery time included random blood glucose level [AHR (95 % CI): 0.58 (0.38–0.90)], duration of diabetes mellitus [AHR (95 % CI): 0.24 (0.14–0.69)], and severity of DKA [AHR (95 % CI): 0.46 (0.16–0.84)].

Conclusion

The median DKA recovery time was prolonged, increasing the risk of complications. Blood glucose level, diabetes duration, and DKA severity were predictors of recovery time. Therefore, targeting these factors through research and interventions may improve outcomes and reduce DKA recovery duration.

背景：糖尿病是一种影响健康的代谢性疾病。到2021年，人口将达到5亿。糖尿病酮症酸中毒是最严重的急性并发症。由于糖尿病酮症酸中毒的重大健康负担，我们对埃塞俄比亚南奥罗米亚州选定公立医院的成年糖尿病患者的康复时间和预测因素进行了回顾性研究。方法对我院2020年1月1日至2023年7月31日收治的316例成人糖尿病酮症酸中毒患者进行回顾性随访研究。使用了一个结构化的检查表。将数据输入Epi-data版本4.6，并使用STATA版本17进行分析，采用Kaplan-Meier生存曲线、log-rank检验和cox -比例风险模型来识别预测因子。双变量和多变量cox回归的结果通过校正风险比报告，置信区间为95%。结果本研究包括316名参与者，其中256名成年人（81.01%）在随访期间康复。总体DKA恢复率为23.8 / 1000人小时（95% CI: 22.21-27.07），中位恢复时间为42小时。恢复时间的显著预测因子包括随机血糖水平[AHR (95% CI): 0.58(0.38-0.90)]、糖尿病病程[AHR (95% CI): 0.24(0.14-0.69)]、DKA严重程度[AHR (95% CI): 0.46(0.16-0.84)]。结论DKA中位恢复时间延长，并发症发生风险增加。血糖水平、糖尿病病程和DKA严重程度是恢复时间的预测因子。因此，针对这些因素，通过研究和干预可以改善结果，缩短DKA恢复时间。

{"title":"Retrospective clinical analysis of time to recovery from diabetic ketoacidosis in Ethiopia","authors":"Angefa Ayele , Dube Jara , Alo Edin , Digafe Hailu , Mihiret Kifle , Yohannes Fekadu","doi":"10.1016/j.endmts.2025.100224","DOIUrl":"10.1016/j.endmts.2025.100224","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes is a metabolic disorder that affected > or = 500 million people in 2021. Diabetic ketoacidosis is the most serious acute complication. Because of the significant health burden of diabetic ketoacidosis, we performed a retrospective study on the recovery time and predictors among adult diabetic mellitus patients in selected public hospitals in Southern Oromia in Ethiopia.</div></div><div><h3>Methods</h3><div>A retrospective follow-up study was conducted of 316 randomly selected adult diabetic ketoacidosis patients admitted between January 1, 2020, and July 31, 2023. A structured checklist was utilized. Data were entered into Epi-data version 4.6 and analyzed with STATA version 17, employing Kaplan-Meier survival curves, log-rank tests, and Cox-proportional hazards models to identify predictors. Results from bivariable and multivariable Cox-regression were reported via adjusted hazard ratio with 95 % confidence intervals.</div></div><div><h3>Results</h3><div>This study included 316 participants, with 256 adults (81.01 %) recovering throughout the follow-up period. The overall DKA recovery rate was 23.8 per 1000 person-hours (95 % CI: 22.21–27.07), and the median recovery time was 42 hr. Significant predictors of recovery time included random blood glucose level [AHR (95 % CI): 0.58 (0.38–0.90)], duration of diabetes mellitus [AHR (95 % CI): 0.24 (0.14–0.69)], and severity of DKA [AHR (95 % CI): 0.46 (0.16–0.84)].</div></div><div><h3>Conclusion</h3><div>The median DKA recovery time was prolonged, increasing the risk of complications. Blood glucose level, diabetes duration, and DKA severity were predictors of recovery time. Therefore, targeting these factors through research and interventions may improve outcomes and reduce DKA recovery duration.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100224"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Geospatial analysis and determinant factors of comorbidity presence in patients with diabetes in Peru 秘鲁糖尿病患者共病存在的地理空间分析和决定因素

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-01-23 DOI: 10.1016/j.endmts.2025.100222

Víctor Juan Vera-Ponce , Fiorella E. Zuzunaga-Montoya , Luisa Erika Milagros Vásquez-Romero , Joan A. Loayza-Castro , Nataly Mayely Sanchez-Tamay , Carmen Inés Gutierrez De Carrillo

Objective

Given the significant increase in diabetes mellitus (DM) prevalence and its associated complications in recent decades, this study aimed to explore the determinant factors and geographical distribution of comorbidities and their number in patients with diabetes in Peru.

Methods

Cross-sectional study based on a database providing detailed demographic and clinical information on DM patients affiliated with the Seguro Integral de Salud (SIS) in Peru. The dependent variables in this study are twofold: the type of comorbidities present in DM patients and the number of comorbidities they have. Comorbidities were categorized into three groups: DM with obesity/dyslipidemia, DM with hypertension, and DM with mental health disorders. The number of comorbidities was classified as none, one, two, or three comorbidities.

Results

A total of 1,355,354 patients were included. Male patients, older individuals, and those with a longer time since diagnosis have different probabilities of presenting the comorbidities and a higher number of them. Additionally, the geospatial analysis showed apparent regional variations in the prevalence and number of comorbidities, highlighting the influence of environmental and socioeconomic factors and access to healthcare services.

Conclusions

This study identified significant demographic and clinical factors associated with comorbidities in patients with DM in Peru. These findings showed the need for personalized, region-specific diabetes management. Therefore, public health policies should adapt to meet the needs of different regions and groups. Improving healthcare access is crucial, especially where comorbidity prevalence is high. Further education programs must address diet and exercise comorbidities, focusing on vulnerable people.

目的：鉴于近几十年来糖尿病（DM）患病率及其相关并发症的显著增加，本研究旨在探讨秘鲁糖尿病患者合并症的决定因素、地理分布及其数量。方法基于一个数据库的横断面研究，该数据库提供了秘鲁Seguro Integral de Salud （SIS）附属糖尿病患者的详细人口统计学和临床信息。本研究的因变量是双重的：糖尿病患者存在的合并症的类型和合并症的数量。合并症分为三组：糖尿病合并肥胖/血脂异常、糖尿病合并高血压和糖尿病合并精神健康障碍。合并症的数量分为无、一、二或三种合并症。结果共纳入1355354例患者。男性患者、老年人和诊断时间较长的患者出现合并症的概率不同，且数量较多。此外，地理空间分析显示，合并症的患病率和数量存在明显的区域差异，突出了环境和社会经济因素以及获得医疗保健服务的影响。结论：本研究确定了与秘鲁糖尿病患者合并症相关的重要人口统计学和临床因素。这些发现表明需要个性化的、针对特定地区的糖尿病管理。因此，公共卫生政策应适应不同区域和群体的需要。改善卫生保健获取至关重要，特别是在合并症患病率高的地方。进一步的教育项目必须解决饮食和运动的并发症，重点关注弱势群体。

{"title":"Geospatial analysis and determinant factors of comorbidity presence in patients with diabetes in Peru","authors":"Víctor Juan Vera-Ponce , Fiorella E. Zuzunaga-Montoya , Luisa Erika Milagros Vásquez-Romero , Joan A. Loayza-Castro , Nataly Mayely Sanchez-Tamay , Carmen Inés Gutierrez De Carrillo","doi":"10.1016/j.endmts.2025.100222","DOIUrl":"10.1016/j.endmts.2025.100222","url":null,"abstract":"<div><h3>Objective</h3><div>Given the significant increase in diabetes mellitus (DM) prevalence and its associated complications in recent decades, this study aimed to explore the determinant factors and geographical distribution of comorbidities and their number in patients with diabetes in Peru.</div></div><div><h3>Methods</h3><div>Cross-sectional study based on a database providing detailed demographic and clinical information on DM patients affiliated with the Seguro Integral de Salud (SIS) in Peru. The dependent variables in this study are twofold: the type of comorbidities present in DM patients and the number of comorbidities they have. Comorbidities were categorized into three groups: DM with obesity/dyslipidemia, DM with hypertension, and DM with mental health disorders. The number of comorbidities was classified as none, one, two, or three comorbidities.</div></div><div><h3>Results</h3><div>A total of 1,355,354 patients were included. Male patients, older individuals, and those with a longer time since diagnosis have different probabilities of presenting the comorbidities and a higher number of them. Additionally, the geospatial analysis showed apparent regional variations in the prevalence and number of comorbidities, highlighting the influence of environmental and socioeconomic factors and access to healthcare services.</div></div><div><h3>Conclusions</h3><div>This study identified significant demographic and clinical factors associated with comorbidities in patients with DM in Peru. These findings showed the need for personalized, region-specific diabetes management. Therefore, public health policies should adapt to meet the needs of different regions and groups. Improving healthcare access is crucial, especially where comorbidity prevalence is high. Further education programs must address diet and exercise comorbidities, focusing on vulnerable people.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100222"},"PeriodicalIF":0.0,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association between metabolic syndrome and gallstone disease: A cross-sectional study from the PERSIAN Guilan cohort study 代谢综合征与胆结石疾病之间的关系：来自波斯桂兰队列研究的横断面研究

Q3 Medicine

Endocrine and Metabolic Science

Pub Date : 2025-01-21 DOI: 10.1016/j.endmts.2025.100221

Hasti Zakeri Fardi , Kourosh Mojtahedi , Saman Maroufizadeh , Farahnaz Joukar , Fariborz Mansour-Ghanaei

Background

There has been a concerning increase in the occurrence of gallstone diseases (GSDs) among individuals with metabolic syndrome (MetS). This study investigated the association between MetS and GSDs and related risk factors.

Methods

This retrospective cross-sectional study was conducted on 10,520 participants from the prospective epidemiological research studies of the Iranian adults (PERSIAN) Guilan cohort study (PGCS) population. Demographic and clinical characteristics, anthropometric parameters, and laboratory findings were collected. National Cholesterol Education Program–Adult Treatment Panel III criteria (NCEP-ATP III) were used to diagnose the MetS. All data was analyzed using SPSS version 26, and a significant level was considered <0.05.

Results

The prevalence of MetS was 41.8 %, with higher rates in females (56.3 %) than males (25.0 %). Also, GSD prevalence was 2.06 %. Abdominal obesity and low high-density lipoprotein (HDL) levels were significantly associated with GSDs (P < 0.05). The presence of MetS increased GSD odds by 47 % (P=0.010). A trend of increasing GSD prevalence with the number of MetS components illustrated a significant relationship ranging from 0.56 % (no components) to 3.60 % (all components) (P < 0.001).

Conclusion

The findings demonstrated that MetS was significantly associated with increased risk of GSDs, of which higher body mass index (BMI), greater waist circumference, and lower HDL level were the most associated risk factors.

背景：在代谢综合征（MetS）患者中，胆结石疾病（GSDs）的发生率有所增加。本研究探讨MetS与GSDs之间的关系及相关危险因素。方法本回顾性横断面研究对来自伊朗成人（波斯）桂兰队列研究（PGCS）人群的前瞻性流行病学研究的10,520名参与者进行了研究。收集了人口统计学和临床特征、人体测量参数和实验室结果。使用国家胆固醇教育计划-成人治疗小组III标准（NCEP-ATP III）诊断MetS。所有数据采用SPSS version 26进行分析，认为显著水平为<；0.05。结果met的患病率为41.8%，女性（56.3%）高于男性（25.0%）。GSD患病率为2.06%。腹部肥胖和低高密度脂蛋白（HDL）水平与GSDs显著相关(P <；0.05)。MetS的存在使GSD的几率增加了47% （P=0.010）。GSD患病率随MetS成分数量的增加呈上升趋势，其显著关系范围为0.56%（无成分）至3.60%（所有成分）(P <；0.001)。结论MetS与gsd发生风险显著相关，其中BMI、腰围和HDL水平降低是与gsd发生风险最相关的因素。

{"title":"The association between metabolic syndrome and gallstone disease: A cross-sectional study from the PERSIAN Guilan cohort study","authors":"Hasti Zakeri Fardi , Kourosh Mojtahedi , Saman Maroufizadeh , Farahnaz Joukar , Fariborz Mansour-Ghanaei","doi":"10.1016/j.endmts.2025.100221","DOIUrl":"10.1016/j.endmts.2025.100221","url":null,"abstract":"<div><h3>Background</h3><div>There has been a concerning increase in the occurrence of gallstone diseases (GSDs) among individuals with metabolic syndrome (MetS). This study investigated the association between MetS and GSDs and related risk factors.</div></div><div><h3>Methods</h3><div>This retrospective cross-sectional study was conducted on 10,520 participants from the prospective epidemiological research studies of the Iranian adults (PERSIAN) Guilan cohort study (PGCS) population. Demographic and clinical characteristics, anthropometric parameters, and laboratory findings were collected. National Cholesterol Education Program–Adult Treatment Panel III criteria (NCEP-ATP III) were used to diagnose the MetS. All data was analyzed using SPSS version 26, and a significant level was considered <0.05.</div></div><div><h3>Results</h3><div>The prevalence of MetS was 41.8 %, with higher rates in females (56.3 %) than males (25.0 %). Also, GSD prevalence was 2.06 %. Abdominal obesity and low high-density lipoprotein (HDL) levels were significantly associated with GSDs (<em>P</em> < 0.05). The presence of MetS increased GSD odds by 47 % (<em>P=</em>0.010). A trend of increasing GSD prevalence with the number of MetS components illustrated a significant relationship ranging from 0.56 % (no components) to 3.60 % (all components) (<em>P</em> < 0.001).</div></div><div><h3>Conclusion</h3><div>The findings demonstrated that MetS was significantly associated with increased risk of GSDs, of which higher body mass index (BMI), greater waist circumference, and lower HDL level were the most associated risk factors.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100221"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0